Free Pulmonology CME

In this online, self-learning activity:

Asthma remains a highly prevalent chronic respiratory disease, affecting more than 26 million people in the United States, including over 4.5 million children, with several thousand deaths and substantial emergency department and inpatient utilization each year despite effective preventives. Persistent symptoms, recurrent exacerbations, and preventable hospitalizations indicate gaps in risk stratification and in the consistent application of guideline-based care, even with comprehensive frameworks such as the Global Initiative for Asthma (GINA) strategy. Many severe attacks still occur, requiring parenteral bronchodilators, systemic corticosteroids, magnesium sulfate, oxygen, and respiratory-support devices, underscoring missed opportunities to optimize maintenance regimens and device use upstream.

This accredited activity reviews advancements in lung transplant surgery, with a focus on robotic lung transplant and ex vivo lung perfusion.

Bronchiectasis is a complex and increasingly prevalent condition often overlooked in clinical practice, with frequent overlap with other respiratory diseases such as COPD and asthma. Persistent airway inflammation, chronic infection, and mucociliary dysfunction drive disease progression, leading to significant morbidity and healthcare burden. As the clinical burden of bronchiectasis becomes increasingly recognized, there is an urgent need to better understand the underlying mechanisms of neutrophilic inflammation, alongside efforts to improve early diagnosis and explore current and emerging treatment options that target this vicious cycle.

In this activity, a panel of leading pulmonologists tackle the evolving challenges and emerging opportunities in bronchiectasis management. From diagnostic workup to airway clearance and exacerbation control, the discussion will blend expert insight with real-world clinical scenarios and patient perspectives.
Endocrinologists, endocrinology NPs and PAs, and the broader care team are positioned to close it. This training program, modeled on the CDC Training of Trainers approach, equips endocrinology-led teams to build CKM risk into everyday T2D decision-making: selecting and sequencing GLP-1-based therapies according to a patient’s cardiovascular, renal, and metabolic profile, not glycemic control alone. The content also addresses related benefits emerging in this drug class, including MASH and OSA, within the broader CKM framework.Designed to update clinicians on data presented at the American Society of Retina Specialists 43rd Annual Meeting held in Long Beach, CA, from July 30 to August 2, 2025
Expert thought leaders provide insights to help clinicians apply these findings to their management of patients with nAMD, DME, and RVO when using newer therapies that support longer treatment intervals.